As­traZeneca show­cas­es 83% risk re­duc­tion for long-act­ing Covid-19 an­ti­body at 6-month analy­sis

Up­dat­ed re­sults from As­traZeneca’s pre­ven­tion tri­al for its long-act­ing Covid-19 an­ti­body com­bo Evusheld sug­gest that the drug is even more ef­fec­tive at the six-month mark, sup­port­ing the case for its use to pro­tect those for whom a vac­cine may be in­suf­fi­cient.

Where­as the pri­ma­ry analy­sis on which FDA and EMA reg­u­la­tors grant­ed emer­gency use au­tho­riza­tion had a me­di­an fol­low-up of 83 days, the ex­tend­ed analy­sis traced them through six months.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.